A woman learns how to rent Mobike in Enshi, central China's Hubei province on July 11, 2017. [Photo/Xinhua] Increasingly popular bike-sharing services in China have helped ease traffic congestion in big cities, according to a recent report. The report, published by Gaode Maps, Chinese Academy of Transportation Sciences and Tsinghua-Daimler Center for Sustainable Transportation, said over 80 percent of China's 100 biggest cities saw improved local traffic conditions in the second quarter of 2017. This is the first time the congestion index has shown signs of going down since Gaode Maps launched the index across the country in 2014. People's means of transportation changed a lot and traffic congestion eased as bike-sharing services expanded in many cities, the report said. While bike-sharing is not rare in other parts of the world, the Chinese version has given a whole new meaning to the concept, with customers able to pick up a bike anywhere in the city, thanks to GPS-enabled apps, and leave it almost anywhere at the end of their journey. The concept is all the rage across the nation among students and young professionals for being convenient, green and cheap. According to Chinese bike-sharing company ofo Inc, among the top 20 cities hosting most of ofo's bikes, 19 of them have seen improved traffic conditions. In Beijing, congestion in over half of the main metro stations during rush hour has decreased by 4.1 percent compared to last year, according to Gaode Maps. band wristbandsmake your own rubber braceletblack rubber wristbandstrio spinnerscheap silicone wristbandswrist band com coupon code
The State Administration for Food and Drug has approved simultaneous port inspection and market sales of Herceptin, the Shanghai Municipal Food and Drug Administration told thepaper.cn Monday.The move saves two to three months from the time required for the drug to reach the hands of customers amid a shortage in the domestic market.Herceptin is a targeted therapy for HER2 positive metastatic breast cancer and HER2 positive gastric cancer. Patients who lack the drug might not recover or could risk shortening their lives.In July 2017, Herceptin was included in the National Reimbursement Drug List. The market price of the drug, which was marked 19,800 yuan ($3,092) for an injection before the inclusion, dropped 60 percent to 7,600 yuan.As the national reimbursement scheme can cover 70 to 80 percent of the drug's cost in most regions, meaning a customer can buy Herceptin at 1,500 yuan for an injection, demand for the drug skyrocketed.Swiss-based drug maker Roche Holding AG, the producer and sole supplier of Herceptin in China's market, said on May 31 that the company has taken several measures to deal with the shortage, including implementing the China market priority strategy, raising the production capacity to full steam, and optimizing logistics channels.The company also filed an application with the State Administration for Food and Drug, asking to relocate the production of Herceptin from its current base to a new one with a higher production capacity. The application was approved May 30.Despite the measures, the company said as it takes longer for production and inspection of the drug, and also time for import and inspection by Chinese authorities before entering the market, it still needs time to fully meet the demand.
